Proleukin (Aldesleukin) for Melanoma

Overview
Proleukin, approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic melanoma, which is melanoma that has spread to other parts of the body. Proleukin is also known by its drug name, aldesleukin.

Aldesleukin belongs to a class of drugs known as lymphocyte growth factors. It works by increasing the growth and activity of white blood cells called lymphocytes, which play a crucial role in the immune response against cancer cells.

How do I take it?
Proleukin is administered through an intravenous infusion in an inpatient hospital setting with an intensive care facility. It’s usually administered every eight hours over five days for up to 14 doses. After a nine-day rest period, the treatment cycle may be repeated. The medication should be taken exactly as prescribed by a health care provider.

Side effects
According to prescribing information, common side effects of Proleukin include hypotension (low blood pressure), hyperbilirubinemia (jaundice), dyspnea (difficulty breathing), rash, diarrhea, oliguria (reduced urine production), chills, vomiting, thrombocytopenia (low platelet count), nausea, confusion, and increased creatinine levels.

Rare but serious side effects may include potentially life-threatening capillary leak syndrome (CLS); neurologic toxicities; and serious infections. Other rare but serious side effects include renal (kidney) damage; immune-mediated adverse reactions; severe hypersensitivity reactions; and embryo-fetal toxicity (fetal harm).

For more information about this treatment, visit:

Highlights of Prescribing Information: Proleukin (Aldesleukin) — U.S. Food and Drug Administration